Straumann Holding AGXSWX:STMN +2.07%100 5-Year Yield-on-Cost % is 1.63 as of Jul. 02, 2026, which is 57% above its 10-year median of 1.04. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.04 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 328 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 60.98% on this metric.
Straumann Holding AG's yield on cost for the quarter that ended in Dec. 2025 was 1.63.
The historical rank and industry rank for Straumann Holding AG's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:STMN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.48 Med: 1.04 Max: 2.16
Current: 1.63
During the past 13 years, Straumann Holding AG's highest Yield on Cost was 2.16. The lowest was 0.48. And the median was 1.04.
XSWX:STMN's 5-Year Yield-on-Cost % is ranked worse than 60.98% of 328
companies
in the Medical Devices & Instruments industry
Industry Median: 2.425
vs XSWX:STMN: 1.63
Straumann Holding AG (XSWX:STMN) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Straumann Holding AG 5-Year Yield-on-Cost % Related Terms
XSWX:STMN vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's 5-Year Yield-on-Cost % falls into.
Straumann Holding AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Straumann Holding AG (XSWX:STMN) has a 5-Year Yield-on-Cost % of 1.63 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Straumann Holding AG and its competitors. This is 57% above median its historical median of 1.04. Over the past decade, Straumann Holding AG's 5-Year Yield-on-Cost % has ranged from 0.48 to 2.16. According to the industry distribution chart, Straumann Holding AG ranks #200 out of 328 companies in the Medical Devices & Instruments industry, placing it in the top 61%.
Is Straumann Holding AG's 5-Year Yield-on-Cost % too high?
Straumann Holding AG's current 5-Year Yield-on-Cost % of 1.63 is 57% above median its 10-year median of 1.04. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 2.16. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.43. Straumann Holding AG's value of 1.63 is 32.8% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #200 out of 328 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #200 out of 328 companies for 5-Year Yield-on-Cost %. This places Straumann Holding AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Straumann Holding AG's value of 1.63 is 32.8% below this benchmark. Historically, Straumann Holding AG's own 5-Year Yield-on-Cost % has ranged from 0.48 to 2.16 over the past decade. While the company's 10-year median is 1.04 vs. the industry median of 2.43, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current 5-Year Yield-on-Cost % of 1.63 is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current 5-Year Yield-on-Cost % is 1.63, which is 57% above median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.04, compared to a current price of CHF108.60 — trading 20.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.63, which is 57% above median its 10-year median of 1.04 and 32.8% below the Medical Devices & Instruments industry median of 2.43. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current 5-Year Yield-on-Cost % is 1.63 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF108.60 is trading 20.8% below its estimated GF Value™ of CHF137.04.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
5-Year Yield-on-Cost %: 1.63 (57% above median its 10-year median of 1.04)
GF Value™: CHF137.04 vs. price of CHF108.60 (20.8% below fair value)
Industry Position: 32.8% below the Medical Devices & Instruments median (#200 of 328)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 